Natera wins FDA Breakthrough Device designation for multi-cancer early detection blood test

What's the deal? The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Natera's multi-cancer early detection (MCED) assay, a blood test that screens for multiple types of cancer from a single sample of cell-free DNA ( DNA shed by cells into the bloodstream.). The designation, announced on​ 9 October​ ️2026, followed FDA assessment of data covering​ 12 cancer types, including the test's sensitivity, specificity and its ability to indicate where in the body a cancer signal originates.

Why it matters: Most cancers are found late, when treatment is harder and survival odds worse. A blood test that could flag several cancers early — and point clinicians toward the affected organ — would be a major advance for screening. Breakthrough Device status is designed to speed development and review of novel technologies that could offer more effective diagnosis or treatment of life-threatening conditions; it gives Natera a faster route to market, more frequent FDA feedback, and priority review when the test eventually goes for clearance. It also extends Natera's franchise in cell-free DNA testing, which currently spans prenatal screening and cancer monitoring, into preventive cancer screening.

Read more: Business Wire via Yahoo Finance, 9 October​ ️2026